#Biodefense System

[covid-safer-hotties]

Kids Are Headed Back to School. Are They Breathing Clean Air? - Published Sept 3, 2024

Across the U.S., kids are headed back to their classrooms—just as COVID nears a fresh, late-summer peak. Somehow, four years into a viral pandemic that everyone now knows spreads through the air, most schools have done little to nothing to make sure their students will breathe safely.

We—and especially our children—should be able to walk into a store or a gym or a school and assume the air is clean to breathe. Like water from the faucet, regulations should ensure our air is safe. “Air is tricky. You can choose to not partake of the water or the snacks on the table, but you can’t just abstain from breathing,” notes Gigi Gronvall, senior scholar at the Johns Hopkins Center for Health Security and an author of a 2021 report on the benefits of improving ventilation in schools.

The COVID-causing virus SARS-CoV-2 is far from the only airborne risk in schools. There are also other respiratory viruses, smoke from wildfires, mold spores, off-gassing from plastics and other compounds, air pollution from traffic and industry, and allergens that worsen asthma and add to sick days. Yet federal air standards are stuck in the 1970s, when they were mostly aimed at protecting people from secondhand tobacco smoke, says Joseph Allen, director of the Healthy Buildings Program at the Harvard T. H. Chan School of Public Health. Fully updated standards for buildings are years or even decades away.

It’s hard to assess just what schools have or haven’t done to improve indoor air quality. No one—not one federal agency—collects nationwide air quality data on individual schools. Schools could use federal money to update air filtration and ventilation during the height of the pandemic. But a 2022 Centers for Disease Control and Prevention survey of school districts found that only half had taken simple steps such as opening windows or doors or using fans, and even fewer had upgraded ventilation systems.

The benefits go beyond protecting children and adults alike from airborne disease spread. “Better ventilation is linked with better test scores and grades [and] better workplace performance,” Allen said at a July meeting about air quality held by the Bipartisan Commission on Biodefense, a U.S. think tank.

“We have made incredible gains related to food safety, sanitation and water quality. Where is air quality in this?” he asked. “We have ignored it.” The CDC and the Food and Drug Administration quickly warn people about listeria in sliced meat or lead in cinnamon, but no one’s checking the air in public buildings for disease-causing germs.

It’s not even hard to make sure indoor air is clean. Even in the 1800s, by having open doors and windows, tuberculosis sanatoriums prevented the spread of disease by air. The CDC has extensive guidelines on what’s known as air exchange, but ultimately, it’s a matter of moving contaminated air out and fresh air in.

If it’s too hot, cold, polluted or humid outside, heating, ventilation and air-conditioning (HVAC) systems can clean up the air perfectly well when they are installed properly and used consistently. Their benefits far outweigh their costs.

“There never has been a building that we could not turn into a healthy building with just a little bit of attention,” said Allen, one of the country’s top crusaders for cleaner air, at the biodefense meeting.

Pandemic fatigue, of course, explains much of the apathy around making air-quality improvements. Public officials, from principals to local legislators right up to the top of the federal government, see that hospitals are no longer overflowing with COVID cases and that the nightly news no longer provides daily death counts. Most parents no longer clamor for assurances that their kids are safe from SARS-CoV-2.

Despite regular, ongoing spikes in COVID, most people have dropped precautions such as masks, even in hospitals.

“People are like, ‘There’s not a whole lot you can do about it,’ and that is why, societally, we need to do something about it,” Gronvall says. “We did this for water once upon a time, and we can do it for air.”

Even the experts have mostly let down their guard.

It wasn’t until halfway through the daylong, in-person-only biodefense conference on air quality that someone even thought to ask if the air in the room was safe to breathe. “Are air monitors effective?” asked former U.S. representative Fred Upton, a Republican and a commissioner at the Bipartisan Commission on Biodefense, at the July meeting. “Does anyone here have one?” added Upton, who had represented Michigan’s sixth district until 2023.

“Are you sure you want to know?” someone in the audience asked, prompting laughter. Rick Rasansky, CEO of XCMR Biodefense Solutions, did have a carbon dioxide monitor, a device that gives a very rough estimate of the amount of fresh air exchange in a room. He read out a “pretty good” measurement.

That was a lucky thing because the 100 or so people attending the meeting had been seated shoulder to shoulder for several hours at that point. Not one was wearing a mask.

It will take federal legislation and sustained attention to make a difference.

The Center for Health Security at Johns Hopkins University have developed a Model Clean Indoor Air Act, which state legislatures throughout the country could use in writing new indoor air laws. In Congress, Representatives Paul Tonko of New York State and Brian Fitzpatrick of Pennsylvania have introduced a bipartisan bill that would require the Environmental Protection Agency to list indoor air contaminants and develop guidelines (albeit voluntary ones).

The new federal Advanced Research Projects Agency for Health (ARPA-H) found a great acronym in its Building Resilient Environments for Air and Total Health (BREATHE) program, which will develop and roll out cool new air-cleaning technologies.

But fancy tech isn’t enough on its own, and some schools may have wasted money on glittery toys instead of real fixes. Ceiling-installed ultraviolet lights won’t kill germs if the air isn’t blown upward to get cleaned in the first place. And gadgetry won’t create the demand and enthusiasm needed for cleaner indoor air. Politicians won’t win elections by campaigning on clean indoor air. But once they have been elected, federal, state and local officials owe it to kids, their parents and their neighbors to fight this most invisible of all hazards.

“We need to make it easier for people to see what they can’t see—to see what they’re breathing,” Gronvall says.

Unpaywalled link: archive.is/20240904045601/https://www.scientificamerican.com/article/kids-are-headed-back-to-school-are-they-breathing-clean-air/#selection-499.0-617.111

[darkmaga-returns]

Key Points:

• ASPR and BARDA, created to respond swiftly to bioterrorism and pandemics, are plagued by inefficiency and bureaucratic overlap.

• The 2001 anthrax attacks exposed systemic dysfunction in biodefense oversight, leading to a power shift from the Department of Defense to the National Institute of Allergy and Infectious Diseases (NIAID).

• Senior Executive Service (SES) employees and cumbersome federal regulations slow decision-making, undermining emergency response efforts.

• The U.S. biodefense system prioritizes stockpiling over innovation, creating a bloated and costly infrastructure that may be ill-prepared for future threats.

• The Covid-19 scandal highlighted the risks of rushed, experimental technologies like mRNA vaccines, raising questions about long-term preparedness.

[mightyflamethrower]

On the evening of July 2, officers from the U.S. Secret Service Uniformed Division found an unknown substance inside a vestibule leading to the lobby area of the West Executive Avenue entrance to the White House. 

The substance was located inside a receptacle used to temporarily store electronic and personal devices prior to entering the West Wing. 

Following the discovery, safety closures were implemented around the White House. This response was designed to ensure that the found substance was not a chemical or radiological material that threatened the security of the White House. As such, the substance was field tested and preliminarily determined to not be a hazardous compound. 

Testing conducted by the District of Columbia Fire and Emergency Medical Services Department indicated that the found powder tested preliminarily positive for the presence of cocaine. The substance and packaging were treated as evidence and sent to the U.S. Department of Homeland Security's National Biodefense Analysis and Countermeasures Center, which analyzed the item for any biothreats. Tests conducted at this facility came back negative and gave formal confirmation that the substance was not biological in nature. 

The substance and packaging underwent further forensic testing. The substance was analyzed for its chemical composition. The packaging was subjected to advanced fingerprint and DNA analysis. Both of these analyses were conducted by the Federal Bureau of Investigation's crime laboratory given their expertise in this area and independence from the investigation. 

While awaiting the FBl's results, the Secret Service investigation into how this item entered the White House continued. The investigation included a methodical review of security systems and protocols. This review included a backwards examination that spanned several days prior to the discovery of the substance and developed an index of several hundred individuals who may have accessed the area where the substance was found. The focal point of these actions developed a pool of known persons for comparison of forensic evidence gleaned from the FBI’s analysis of the substance's packaging. 

On July 12, the Secret Service received the FBI’s laboratory results, which did not develop latent fingerprints and insufficient DNA was present for investigative comparisons.   Therefore, the Secret Service is not able to compare evidence against the known pool of individuals. The FBl's evaluation of the substance also confirmed that it was cocaine. 

There was no surveillance video footage found that provided investigative leads or any other means for investigators to identify who may have deposited the found substance in this area. Without physical evidence, the investigation will not be able to single out a person of interest from the hundreds of individuals who passed through the vestibule where the cocaine was discovered. At this time, the Secret Service's investigation is closed due to a lack of physical evidence. 

The U.S. Secret Service takes its mission to protect U.S. leaders, facilities, and events seriously and we are constantly adapting to meet the needs of the current and future security environment. 

Blah blah blah blahdy blah blah. Have you ever caught your child doing something wrong and their alabi goes on and on. The longer they talk the guiltier they sound. That would be the best analogy of what we just got from the DOJ. We all know who's coke this is. If it were anyone else's they would have already forced him to do a very public perp walk. We'd be listening to interviews with their third grade teachers. Every inch of the White House is under CCTV 24/7. Hunter has a long history of getting fucked up and forgetting what he did with things.

Our inability to ever get the truth out of this administration is both alarming and disgusting.

Good Job democrats.

[rainyducktiger]

Biodefence Market Resilience and Risk Factors Impacting Growth to 2033

The global biodefense market is experiencing significant growth, driven by escalating concerns over biological threats, increased government investments, and advancements in biotechnology. Forecasts indicate that the market will continue its upward trajectory through 2032, reflecting its critical role in national security and public health.

Market Overview

Biodefense encompasses strategies and medical interventions designed to protect populations from biological threats, including bioterrorism and infectious disease outbreaks. These measures involve the development and deployment of vaccines, medications, and health preparedness initiatives to counteract pathogens like bacteria, viruses, and toxins.

As of 2024, the global biodefense market was valued at approximately USD XX billion. Projections suggest that by 2032, the market will reach USD XX billion, exhibiting a compound annual growth rate (CAGR) of XX% during the forecast period.

Download a Free Sample Report:-https://tinyurl.com/yzed4fwf

Key Drivers of Market Growth

Rising Bioterrorism Concerns: The potential use of biological agents as weapons has heightened the need for robust biodefense mechanisms. Governments worldwide are prioritizing biodefense strategies, allocating substantial budgets to research and development to safeguard their populations.

Technological Advancements: Innovations in vaccine development, biosurveillance systems, and diagnostic tools have propelled the biodefense market forward. Real-time pathogen detection technologies are becoming integral to public health responses, enabling swift action during biological threats.

Government Initiatives and Funding: Increased funding for research and development, preparedness planning, infrastructure development, and procurement of vaccines and medications drives the growth of the biodefense market.

Market Segmentation

The biodefense market is segmented based on disease type and treatment:

By Disease Type:

Anthrax: This segment held the majority share in 2023, attributed to rising concerns about biological weapon use and growing animal exposure incidents.

Smallpox: Ongoing vaccination initiatives and stockpiling efforts contribute to this segment's growth.

Botulism: Focused on developing antitoxins and preventive measures.

Influenza: Continuous efforts in vaccine development to combat seasonal and pandemic strains.

Radiation/Nuclear: Preparedness strategies for radiological threats.

By Treatment:

Vaccination: This segment is projected to be the faster-growing segment during the forecast period, attributed to the increasing threat of emerging infectious diseases, rising development of novel pathogens, and increasing global immunization initiatives.

Medication: Includes antibiotics, antivirals, and antitoxins developed to treat infections resulting from biological agents.

Regional Insights

North America dominates the biodefense market, with the U.S. leading due to significant government investments in national security and public health. The U.S. military sector remains the largest consumer, accounting for nearly 45% of the total market share.

Europe holds the second-largest market share, driven by the prevalence of chronic diseases and the rise in research and development activities for biodefense solutions across the region.

Challenges and Opportunities

While the biodefense market is poised for growth, it faces challenges such as the high cost of research and development, regulatory hurdles, and public perception issues regarding certain interventions. However, opportunities abound in developing AI-based diagnostic tools, next-generation vaccines, and portable detection systems.

Conclusion

The biodefense market is set to expand significantly through 2032, driven by heightened awareness of biological threats and substantial investments in defense mechanisms. As technological advancements continue and global collaborations strengthen, the industry will play a pivotal role in safeguarding public health and ensuring national security.

Read Full Report:-https://www.uniprismmarketresearch.com/verticals/healthcare/biodefence.html

[indoorverticalfarmingnews]

Meristem Crop Performance Launches BIO-CAPSULE™ Technology for Pest Control

Key Takeaways Meristem Crop Performance introduced the MAX Family BioDefense product line, integrating biological and synthetic pest control solutions. The BIO-CAPSULE™ Technology allows pest control treatments without the need for liquid application systems. The product line targets major crop pests, including corn rootworm, soybean cyst nematode, and sudden death syndrome. Multi-year research…

[meditechinsight01]

Global Biosensors Market: 8% CAGR and the Role of Biosensors in Real-Time Disease Monitoring by 2030

The global biosensors market is projected to grow at a CAGR of 8% from 2025 to 2030, driven by the growing adoption of biosensors in point-of-care diagnostics, advancements in nanotechnology, and increasing demand for wearable health monitoring devices. The integration of artificial intelligence (AI) and Internet of Things (IoT) technologies into biosensor systems further fuels market expansion.

Biosensors are analytical devices that consists of biological and physicochemical components and are widely utilized in healthcare, environmental monitoring, food safety, and biodefense applications. The market is driven by the increasing prevalence of chronic diseases, growing demand for personalized medicine, and rising interest in continuous health monitoring. Furthermore, advancements in microfluidics, biocompatible materials, and miniaturization techniques are enhancing the sensitivity, specificity, and usability of biosensors, driving market adoption.

To request a free sample copy of this report, please visit below https://meditechinsights.com/biosensors-market/request-sample/

Rising Demand for Wearable Biosensors Transforming Healthcare Delivery

Wearable biosensors, a key segment within the biosensors market, are revolutionizing healthcare delivery by enabling continuous health monitoring. Devices such as glucose monitors, heart rate trackers, and fitness bands provide real-time insights into physiological parameters, supporting early disease detection and management. The integration of wearable biosensors into telemedicine platforms is also expanding access to healthcare services in remote and underserved areas. With the growing consumer preference for preventive healthcare and personalized medicine, wearable biosensors are expected to remain a dominant market segment.

Technological Innovations Driving Biosensor Market Growth

Technological innovations are revolutionizing the biosensors market by improving performance, usability, and cost efficiency. Advancements in nanotechnology and microfluidics have enabled the development of compact, highly sensitive biosensors for a wide range of applications. The integration of AI and IoT has enhanced data collection and real-time analysis, facilitating precise health monitoring and disease management. Miniaturization techniques and biocompatible materials are driving the creation of wearable and implantable biosensors with superior functionality and patient comfort. Additionally, breakthroughs in non-invasive sensing technologies, such as optical and electrochemical biosensors, are expanding the scope of biosensor applications in diagnostics, environmental monitoring, and food safety.

Competitive Landscape Analysis

Leading players in the biosensors market, including Abbott, Medtronic, GE Healthcare, Thermo Fisher Scientific, and F. Hoffmann-La Roche Ltd, are actively engaged in strategic collaborations, R&D investments, and product launches to strengthen their market positions.

🔗 Want deeper insights? Download the sample report here: https://meditechinsights.com/biosensors-market/request-sample/ 

Global Biosensors Market Segmentation

This report by Medi-Tech Insights provides the size of the global biosensors market at the regional- and country-level from 2023 to 2030. The report further segments the market based on product, type, and application.

Market Size & Forecast (2023-2030), By Product, USD Billion

Wearable Biosensors

Non-wearable Biosensors

Market Size & Forecast (2023-2030), By Type, USD Billion

Optical Biosensors

Electrochemical Biosensors

Piezoelectric Biosensors

Thermal Biosensors

Nanomechanical Biosensors

Others

Market Size & Forecast (2023-2030), By Application, USD Billion

Healthcare

Glucose Monitoring

Infectious Disease Detection

Pregnancy Testing

Cardiac Monitoring

Other Medical Applications

Environmental Monitoring

Food & Beverages

Other Applications

Market Size & Forecast (2023-2030), By Region, USD Billion

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia Pacific

China

India

Japan

Rest of Asia Pacific

Latin America

Middle East & Africa

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde  Associate, Medi-Tech Insights  +32 498 86 80 79  info@meditechinsights.com 

[anujmrfr]

Bio Detectors and Accessories Market Size, Growth Outlook 2035

The global the Bio Detectors and Accessories Market Size was estimated at 3.57 (USD Billion) in 2024. The Bio Detectors and Accessories Market Industry is expected to grow from 4.04 (USD Billion) in 2025 to 12.30 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 13.18% during the forecast period (2025 - 2034).

Market Overview The Bio Detectors and Accessories Market is experiencing significant growth due to the increasing need for early detection of biological threats, pathogens, and biohazards. These devices are used in various applications, including biodefense, clinical diagnostics, environmental monitoring, and food safety testing. The rising incidence of infectious diseases, growing concerns over bioterrorism, and advancements in biosensor technology are key factors driving market expansion.

Market Size and Share The global the Bio Detectors and Accessories Market Size was estimated at 3.57 (USD Billion) in 2024. The Bio Detectors and Accessories Market Industry is expected to grow from 4.04 (USD Billion) in 2025 to 12.30 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 13.18% during the forecast period (2025 - 2034). North America dominates the market due to strong government initiatives in biodefense programs, while the Asia-Pacific bio detection market is expected to witness the highest growth due to increasing investments in biological threat detection systems.

Market Drivers

Rising Threat of Bioterrorism and Biological Warfare: Governments worldwide are investing in biohazard detection technologies to enhance national security.

Increasing Prevalence of Infectious Diseases: The need for early pathogen detection systems has surged, particularly in the wake of global health crises.

Advancements in Biosensor Technologies: Development of nanotechnology-based biosensors and portable bio detectors is improving detection accuracy and efficiency.

Growing Applications in Food Safety and Environmental Monitoring: Bio contamination detection systems are increasingly used to ensure food safety and environmental protection.

Challenges and Restraints

High Costs Associated with Advanced Bio Detection Systems: The cost-intensive nature of bio detection equipment limits adoption in low-income regions.

Stringent Regulatory Approvals: The approval process for bio detection devices can be complex and time-consuming.

Limited Awareness and Technical Expertise: A lack of skilled professionals in handling biosensor-based bio detectors can hinder market expansion.

Market Trends

Miniaturization and Portability of Bio Detectors: The development of handheld bio detection devices is making biological threat detection more accessible.

Integration of Artificial Intelligence in Bio Detection: AI-powered biosensors are enhancing real-time biological contamination analysis.

Increased Use of Multiplex Bio Detection Platforms: Advanced systems capable of detecting multiple pathogens simultaneously are gaining traction.

Regional Analysis

North America: The dominant region due to strong government funding for biodefense technologies and increasing R&D in bio detection devices.

Europe: Significant demand for bio surveillance systems in clinical and environmental applications.

Asia-Pacific: Fastest-growing market due to increasing healthcare infrastructure development and rising concerns over infectious disease outbreaks.

Rest of the World: Growing investments in bio detection technologies for food and water safety.

Segmental Analysis

By Product Type:

Portable Bio Detectors

Fixed Bio Detection Systems

Biosensors and Accessories

By Technology:

Microbial Detection

PCR-Based Detection

Immunoassay-Based Detection

Electrochemical and Optical Biosensors

By End-User:

Military & Defense Organizations

Healthcare & Clinical Diagnostics

Environmental Agencies

Food & Agriculture Industries

Key Market Players

QIAGEN

Enzo Biochem, Inc.

Roche Diagnostics

Merck KGaA

Becton, Dickinson and Company

Thermo Fisher Scientific

Recent Developments

Launch of AI-Driven Bio Detection Devices: Companies are integrating AI in pathogen detection biosensors for rapid diagnosis.

Expansion of Biodefense Research Programs: Governments worldwide are increasing funding for biothreat detection systems.

Strategic Collaborations in Bio Surveillance: Leading players are forming partnerships to enhance capabilities in biological contamination detection.

For more information, please visit us at marketresearchfuture.

[mordorintelligencemarketresearch]

The Biodefense Industry: Safeguarding Nations Against Biological Threats 

The biodefense industry stands at the intersection of healthcare, security, and technology, addressing a critical need to protect populations against biological threats, whether naturally occurring, accidental, or deliberate. From emerging infectious diseases to bioterrorism, the industry plays a pivotal role in enhancing national and global security. As geopolitical tensions persist and the risk of pandemics grows, the importance of biodefense has never been more pronounced. 

The biodefense market is projected to be valued at USD 17.79 billion in 2024 and is expected to expand to USD 26.30 billion by 2029, achieving a compound annual growth rate (CAGR) of 8.13% during the forecast period from 2024 to 2029

What is Biodefense? 

Biodefense refers to the measures and strategies implemented to mitigate the risks posed by biological agents, including viruses, bacteria, and toxins. It encompasses a wide range of activities, including: 

Detection and Surveillance: Identifying biological threats through advanced monitoring systems. 

Prevention and Protection: Developing vaccines, therapeutics, and protective equipment to safeguard populations. 

Preparedness and Response: Creating contingency plans, training personnel, and establishing rapid response systems for biological emergencies. 

Biodefense strategies are employed by governments, healthcare organizations, and private entities to ensure public safety and maintain stability during biological crises. 

Key Drivers of the Biodefense Industry 

1. Rising Threat of Emerging Infectious Diseases 

The world has witnessed a surge in zoonotic diseases and pandemics, such as SARS, H1N1, Ebola, and COVID-19. These outbreaks have underscored the need for robust biodefense systems to detect, prevent, and respond to infectious diseases that can spread globally in a matter of days. 

2. Concerns Over Bioterrorism 

The possibility of deliberate biological attacks using engineered pathogens or toxins remains a significant concern for governments worldwide. Biodefense initiatives aim to mitigate the risks of bioterrorism by investing in surveillance systems, research, and countermeasure development. 

3. Government Support and Funding 

Governments worldwide are allocating substantial budgets to strengthen biodefense capabilities. Initiatives like the U.S. Strategic National Stockpile (SNS) and programs under agencies like BARDA (Biomedical Advanced Research and Development Authority) have spurred growth in the industry. 

4. Technological Advancements 

Innovations in biotechnology, genomics, and artificial intelligence are transforming the biodefense landscape. These technologies enable rapid pathogen identification, vaccine development, and real-time threat analysis, boosting the industry's effectiveness. 

5. Public Health Awareness 

The COVID-19 pandemic has heightened public awareness of the devastating impact of biological threats. This has led to increased demand for vaccines, diagnostics, and protective measures, fueling growth in the biodefense sector. 

Applications of Biodefense 

1. Vaccine Development and Production 

Vaccines are a cornerstone of biodefense, providing immunity against infectious agents. During biological emergencies, the rapid development and distribution of vaccines are critical for mitigating the impact of outbreaks. 

2. Diagnostic Technologies 

Advanced diagnostics play a vital role in detecting biological threats early and accurately. Point-of-care testing, molecular diagnostics, and biosensors are integral to surveillance and response systems. 

3. Biosurveillance 

Biodefense relies heavily on surveillance systems to monitor and identify potential biological threats. These systems use data from healthcare facilities, laboratories, and environmental monitoring to track disease patterns and detect unusual activity. 

4. Therapeutics and Antidotes 

In addition to vaccines, the industry focuses on developing therapeutics and antidotes to treat individuals exposed to biological agents. These include antiviral drugs, monoclonal antibodies, and toxin-neutralizing agents. 

5. Training and Infrastructure 

Preparedness measures include training healthcare professionals, military personnel, and first responders to handle biological emergencies effectively. Robust infrastructure, including biocontainment labs and emergency response centers, supports these efforts. 

Challenges in the Biodefense Industry 

1. High Development Costs 

Developing vaccines, therapeutics, and diagnostics for biological agents is a resource-intensive process requiring significant investment. High costs can hinder innovation and limit the availability of countermeasures. 

2. Regulatory Complexity 

Biodefense products must meet stringent regulatory standards to ensure safety and efficacy. Navigating the approval process can be time-consuming and challenging, especially during emergencies requiring rapid deployment. 

3. Evolving Biological Threats 

Pathogens are constantly evolving, with the emergence of drug-resistant strains posing additional challenges. The industry must adapt quickly to these changing threats to maintain its effectiveness. 

4. Public Perception and Misinformation 

Biodefense efforts often face skepticism and misinformation, particularly regarding vaccines and government initiatives. Building public trust is essential for the success of biodefense programs. 

5. Ethical and Dual-Use Concerns 

Biotechnology advancements can be misused for harmful purposes, raising ethical concerns about dual-use research. Striking a balance between innovation and security is a persistent challenge for the industry. 

Innovations and Emerging Trends in Biodefense 

1. Artificial Intelligence and Machine Learning 

AI is revolutionizing biodefense by enabling predictive modeling, real-time threat analysis, and accelerated drug discovery. Machine learning algorithms can identify patterns in disease outbreaks, aiding early detection. 

2. mRNA Technology 

The success of mRNA-based COVID-19 vaccines has highlighted the potential of this technology in biodefense. mRNA platforms enable rapid vaccine development, offering a flexible solution for combating emerging pathogens. 

3. Portable Diagnostics 

The development of portable diagnostic tools, such as handheld biosensors and wearable devices, is enhancing the ability to detect biological threats in real time, even in remote or resource-limited settings. 

4. CRISPR-Based Tools 

CRISPR technology is being explored for its potential in rapid pathogen detection and the development of targeted therapeutics. Its precision and versatility make it a valuable asset in biodefense. 

5. Global Collaboration 

International cooperation is becoming increasingly important in addressing global biological threats. Collaborative efforts between governments, organizations, and private entities aim to strengthen biodefense capabilities across borders. 

The Role of Biodefense During the COVID-19 Pandemic 

The COVID-19 pandemic served as a wake-up call for the importance of biodefense. It demonstrated the need for robust surveillance systems, rapid vaccine development, and coordinated global responses to biological crises. The lessons learned during the pandemic have accelerated investments in biodefense infrastructure and technologies, ensuring better preparedness for future threats. 

Conclusion 

The biodefense industry is a critical component of global health security, addressing the growing risks posed by biological agents. With advancements in technology, increased government funding, and rising public awareness, the industry is poised for significant growth. 

While challenges such as high costs, regulatory complexities, and evolving threats persist, innovations like AI, mRNA technology, and CRISPR are paving the way for more effective and efficient biodefense solutions. As the world faces an uncertain future with potential biological threats on the horizon, the biodefense industry will remain indispensable in safeguarding populations and ensuring resilience against emerging challenges. 

For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence: https://www.mordorintelligence.com/industry-reports/biodefense-market 

[secretofresearch]

Biodefense: Understanding the Role of Biodefence Against Biological Threats In Industry

Biological threats pose a serious danger to national and global security. Biological agents like viruses, bacteria, toxins and other disease-causing organisms can potentially sicken or kill large numbers of people if used as weapons. Some examples of pathogenic biological agents that have been militarized or have potential as bioweapons include anthrax, plague, smallpox, tularemia and staphylococcal enterotoxin B. These agents are highly dangerous due their ability to sicken or kill on exposure, difficulty of detection and potential transmission between people. Several rogue states and terrorist organizations are suspected to be pursuing offensive biological weapons programs, raising the risk of hostile use or accidental release of dangerous pathogens. The threat of biological weapons has grown in the modern world due to advances in biotechnology which has enabled easier production of biological agents that can potentially be used for hostile purposes. This underscores the importance of biological defense against such threats through early detection, prevention and preparedness measures.

Goals and Objectives of Biodefense

Biological defense involves coordinated efforts across scientific, medical, security and policy domains aimed at addressing biological threats through non-proliferation, countermeasures and response capabilities. The overarching goals of biological defense are to minimize vulnerabilities, detect biological incidents early, mitigate impacts and enable rapid recovery. Specific objectives include developing capabilities for early warning and detection of outbreaks using disease surveillance and biosensors. Biodefense also involves stockpiling effective medical countermeasures like vaccines, antiviral drugs and therapeutic antibodies. Biological defense research contributes to the development of new and improved vaccines, diagnostics, prophylactic and therapeutic agents. Response planning and coordination between healthcare, law enforcement and other stakeholders ensures preparedness for potential biological incidents. International cooperation and treaties seek to prevent the spread and hostile use of pathogens through export controls and verification mechanisms.

Surveillance and Detection Systems

One of the most important components of biological defense is early detection through disease monitoring and biosensors. The United States operates an integrated biosurveillance program involving multiple agencies that provide early warning of disease outbreaks. Systems like the National Syndromic Surveillance Program monitor emergency room visits and pre-hospital care reports for signs of epidemics. Additional programs track influenza-like illnesses and analyze data from Medical Information Surveillance Integrated System, Google Flu Trends and other sources to identify potential outbreaks rapidly. Biodefence agencies are also investing in research to develop advanced nucleic acid, protein and antibody-based biosensors for rapid, sensitive and specific detection of potential biological weapons agents. Some future technologies under development include handheld devices that can detect airborne pathogens as well as systems for continuous, real-time monitoring of public areas such as airports or subways for signs of biological incidents. Early detection is critical to reduce impact because it allows for immediate healthcare mobilization and faster dispensation of medical countermeasures.

Medical Countermeasures Strategies

Biological defense stockpiles form a crucial component of defense by ensuring timely access to antibiotics, antivirals, antitoxins, vaccines and other medical countermeasures in the event of a biological attack. The US Strategic National Stockpile maintains large caches of pharmaceuticals, medical supplies and equipment for rapid response and dispensing after exposure to pathogens. Key medical countermeasures for high-priority biological threats include anthrax vaccines, smallpox vaccines, antiviral drugs for influenza and botulism antitoxins. There is a continuing focus on developing improved countermeasures for emerging and engineered threats as well as combating antimicrobial resistance. For instance, efforts are underway to develop next generation anthrax vaccines with broader effectiveness and fewer doses required. Research is also being conducted to design versatile platform technologies like monoclonal antibody therapies, adjuvant systems and genomic analysis tools to speed up countermeasure development against unknown future threats. International cooperation helps expand countermeasure access globally and strengthens preparedness worldwide against biological incidents.

Response Planning and Preparedness Exercises

Effective biological defense requires coordinated response planning across various levels from federal agencies down to state and local public health networks. Response plans delineate roles, responsibilities and standard operating procedures during potential biological incidents to enable rapid detection, healthcare mobilization, casualty treatment and mitigation efforts. Emergency Operations Centers are equipped and staffed to coordinate large-scale incident management in real-time. Preparedness exercises test response plans, find gaps, improve coordination and train frontline professionals through simulated biological scenarios. Some examples are biennial Crimson Contagion drills conducted by the US Department of Health and Human Services simulating nationwide outbreaks, TOPOFF full-scale exercises simulating complex terrorism incidents, and annual Pandemic Influenza Readiness Exercises focused on healthcare surge capacity. As part of continuity of government planning, agencies have developed detailed contingency plans for sustaining essential services during staff shortages or infrastructure disruptions due to a biological attack. Regular drills at federal, state and community levels help strengthen all-hazards preparedness nationwide.

Challenges and Future Directions

While considerable progress has been made, biological defense efforts still face scientific, technical and policy related challenges. Rapid evolution of microbiological threats requires agility to update detection and response systems. Scientific dilemmas persist with bioforensics, attribution, biotechnology oversight and managing dual-use risks. Costs of upgrading surveillance infrastructure countrywide are high. Stockpiling of multi-purpose medical countermeasures needs accelerated investment while ensuring incentives for industry involvement. Globalisation and interconnectivity necessitate greater international cooperation on biosecurity best practices, export controls and pathogen transparency. Future priorities include developing artificial intelligence assisted analytics, blockchain enabled public health data-sharing, novel diagnostics based on microfluidics, mobile detection laboratories and telemedicine facilities to empower distributed biological defense capabilities

In the face of growing biological risks, a robust biological defense encompassing coordinated preventive mechanisms, preparedness planning and technological solutions provide strategic depth against intentional outbreaks and natural disease emergencies. While continual progress is needed, past investments in early warning systems, medical countermeasures development and coordinated exercises have undoubtedly strengthened resilience of nations. With prudent management of evolving threats and challenges, further optimization of integrated biological defense has the potential to significantly curb impacts from biological incidents in the decades ahead. Global health security also depends on collaborative efforts that foster transparency, reinforce international norms and enable rapid sharing of expertise during public health emergencies. A multilateral approach will be integral to the long term success of this critical mission.

Get more insights on Biodefense

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[jcmarchi]

Eric Evans receives Department of Defense Medal for Distinguished Public Service

New Post has been published on https://thedigitalinsider.com/eric-evans-receives-department-of-defense-medal-for-distinguished-public-service/

Eric Evans receives Department of Defense Medal for Distinguished Public Service

On May 31, the U.S. Department of Defense’s chief technology officer, Under Secretary of Defense for Research and Engineering Heidi Shyu, presented Eric Evans with the Department of Defense (DoD) Medal for Distinguished Public Service. This award is the highest honor given by the secretary of defense to private citizens for their significant service to the DoD. Evans was selected for his leadership as director of MIT Lincoln Laboratory and as vice chair and chair of the Defense Science Board (DSB).

“I have gotten to know Eric well in the last three years, and I greatly appreciate his leadership, proactiveness, vision, intellect, and humbleness,” Shyu stated in her remarks during the May 31 ceremony held at the laboratory. “Eric has a willingness and ability to confront and solve the most difficult problems for national security. His distinguished public service will continue to have invaluable impacts on the department and the nation for decades to come.” 

During his tenure in both roles over more than a decade, Evans has cultivated relationships at the highest levels within the DoD. Since stepping into his role as laboratory director in 2006, he has advised eight defense secretaries and seven deputy defense secretaries. Under his leadership, the laboratory delivered advanced capabilities for national security in a broad range of technology areas, including cybersecurity, space surveillance, biodefense, artificial intelligence, laser communications, and quantum computing.

Evans ensured that the laboratory addressed not only existing DoD priorities, but also emerging and future threats. He foresaw the need for and established three new technical divisions covering Cyber Security and Information Sciences, Homeland Protection, and Biotechnology and Human Systems. When the Covid-19 pandemic struck, he quickly pivoted the laboratory to aid the national response. To ensure U.S. competitiveness in an ever-evolving defense landscape, he advocated for the modernization of major test ranges, including the Reagan Test Site for which the laboratory serves as scientific advisor, and secured funding for new state-of-the-art facilities such as the Compound Semiconductor Laboratory – Microsystem Integration Facility. He also strengthened ties with MIT campus on research collaborations to drive innovation and expand educational opportunities for preparing the next generation of the DoD STEM workforce.

In parallel, Evans served on the DSB, the leading board for providing science and technology advice to DoD senior leadership. Evans served as DSB vice chair from 2014 to 2020 and chair since 2020. Over the years, Evans led or supported more than 30 DSB studies of direct importance to the DoD. Most notably, he initiated a new Strategic Options Permanent Subcommittee focused on identifying systems and technology to prepare the nation for future defense needs.

“The medal is a wonderful and richly deserved recognition of Eric’s contributions to MIT and to national security,” said Ian Waitz, MIT’s vice president for research.

As Evans steps down from his role as Lincoln Laboratory director on July 1, he will transition to a joint appointment as a senior fellow and professor of practice appointment on the MIT campus and as a fellow in the Director’s Office at Lincoln Laboratory. In these new roles, he will continue to strengthen ties between the laboratory and MIT campus and work with DoD leaders.

[joytalukdar]

State well-being authorities report probably the reason for the first human plague disease in quite a while

DESCHUTES District, Metal. (WKRC) - One state as of late announced its most memorable human instance of the bubonic plague in about eight years.

Deschutes District Wellbeing Administrations in Oregon accept the individual contracted it from a pet feline. Wellbeing official Dr. Richard Fawcett says the feline was "exceptionally wiped out" and had a canker that was depleting.

He additionally reported that its proprietor's disease had arrived at the circulatory system when the individual got to the emergency clinic. A few specialists clearly figured the patient fostered a hack, which could be a sign the illness advanced and changed to the pneumonic plague.

The pneumonic plague is frequently lethal and can be sent from one individual to another. Notwithstanding, Dr. Fawcett says it's not satisfactory assuming that worked out.

Creatures can get the bubonic plague assuming they're chomped by an insect conveying the bacterium that causes it, or they get a tainted rat.

The sickness is moved to people through tissue or natural liquids, similar to the caring delivered during hacks and wheezes. Pets can likewise bring back the Yersinia pestis bacterium-conveying insects, which may then chomp the proprietor.

Wellbeing authorities say felines are more powerless against the plague in light of the fact that their bodies experience issues battling it, and they're bound to chase rodents.

The individual who was as of late determined was blessed to receive have anti-microbial. Specialists additionally offered those nearby the patient.

Those tainted with the bubonic plague will have difficult expanding in the lymph hubs, and can be handily relieved with anti-toxins more often than not.

Nonetheless, in the event that it is left untreated and advances into the circulatory system, it can cause possibly lethal difficulties.

"Exactly the same thing caused the Dark Demise, however that was in the pre-anti-toxin period," said David Wagner, overseer of the Biodefense and Sickness Nature Center at Northern Arizona College.

Dr. Fawcett says the gamble of a spread in Oregon is possible extremely low. The U.S. by and large, around seven human instances of the plague every year.

"We actually don't have a decent handle of plague diligence in the climate in the western U.S.," Wagner said. "It's simply so enigmatic. It sort of vanishes into these populaces of rodents and we simply don't have any idea what's happening out there."

Pet people are encouraged to keep creatures on rope when outside, use bug control items, and take them to a vet right away in the event that they become debilitated in the wake of contacting a rat From news

[darkmaga-returns]

Just for this post, I’m departing from my typical, story-based portrayal of the Scamdemic as an event that gullible people swallowed and tolerated. I’m writing to support a project that a fellow Covid dissident and trusted friend, Debbie Lerman, is working on with Sasha Latypova.

Debbie does serious research based on primary documents. On several occasions, I’ve heard Debbie speak, with conviction and specificity, of the top/down source of Covid “mitigation” measures that made no biological/social/public health sense to anyone who thought just a little about these.

Debbie and Sasha call their project “The Covid Dossier.” It’s a compilation of the information Debbie and Sasha have gathered demonstrating that the Covid response was a) led by military/intelligence arms of government and b) coordinated through military/intelligence alliances, primarily NATO and various biodefense agreements. I have sometimes alluded to Debbie’s perspective in my posts.

Debbie and Sasha’s materials derive from many countries and thus, illustrate the global reach of control systems responsible for Covid.

February 4, 2025 is the fifth anniversary of the first EUA/PREP Act emergency declaration. This declaration can be seen as the official beginning of the biodefense lockdown-until-vaccine response, though no one but the perpetrators knew it at the time.

[systemtek]

Frontier AI Taskforce brings in leading technical organisations to research risks

The UK government’s Frontier AI Taskforce is building an AI safety research team that can evaluate risk at the frontier of AI. Doing great AI safety research does not mean starting from scratch or working alone. As set out in its first progress report on 7 September 2023 the taskforce is working with leading technical organisations including ARC Evals, RAND and Trail of Bits.  Since then, the taskforce has partnered with a further three leading technical organisations. These new contracts with Advai, Gryphon Scientific and Faculty AI will tackle important questions about how AI systems can improve human capabilities in specialised fields and risks around current safeguards. The findings of the research will be incorporated into presentations and roundtable discussions with government representatives, civil society groups, leading AI companies and experts in research at the AI Safety Summit in November.   Advai is a UK company focussed on enabling Simple, Safe, Secure AI adoption. Their technology and research focusses on identifying vulnerabilities and limitations in AI to improve and defend these systems. The Frontier AI Taskforce is working with Advai to research vulnerabilities of frontier AI systems.  Faculty is an applied AI company, providing software, consulting, and services. It has worked with the UK government for nearly a decade, with its other public sector work including partnering with the NHS to build the COVID-19 early warning system, and with the Home Office to detect ISIS online propaganda. The Frontier AI Taskforce is working with Faculty AI to identify to what degree LLMs can uplift a novice bad actor’s capability, and how future systems may increase this risk.  Gryphon Scientific is a physical and life sciences research and consulting company with technical expertise in public health, biodefense, and homeland security. They have experience in working at the forefront of scientific advancement alongside governments, including the US, and nations in the Middle East and North Africa. Gryphon Scientific is working with the Frontier AI Taskforce to identify the potential for LLMs as a tool to drive rapid progress in the life sciences.  Today’s announcement follows the progress report on the 07 September, where the Frontier AI Taskforce announced the establishment of its expert advisory panel, the appointment of two research directors, and several partnerships with organisations. Read the full article

[pranay-234]

Anthrax Vaccine Market: Strategic Imperatives for Success and Rising Demand During 2023-2032

In a world where global health security is paramount, the Anthrax Vaccine Market has emerged as a critical player in safeguarding lives and livelihoods against the threat of anthrax, a potentially deadly disease caused by the bacterium Bacillus anthracis. Anthrax has not only been a concern for public health but also a potential bioterrorism weapon. As the world faces evolving challenges, the insights derived from this market are instrumental in strengthening defenses and protecting populations.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐎𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 : https://www.alliedmarketresearch.com/request-toc-and-sample/12033

𝐂𝐎𝐕𝐈𝐃-𝟏𝟗 𝐈𝐦𝐩𝐚𝐜𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬

COVID-19, caused by the SARS-CoV-2 virus, originated in Wuhan, China, in late 2019. Since then, it has rapidly spread to nearly 213 countries, prompting the World Health Organization to declare it a global public health emergency on March 11, 2020.

Pharmaceutical and biotech companies, in collaboration with governments, have been tirelessly addressing the COVID-19 outbreak. Efforts have been focused on vaccine development and managing medicine supply chain challenges. Currently, there are around 115 vaccine candidates and 155 molecules in the research and development pipeline. Additionally, drugs like hydroxychloroquine have experienced a surge in demand for COVID-19 management, creating opportunities for manufacturers to meet this increased need, particularly in developed countries facing shortages.

This heightened demand for COVID-19 management drugs is expected to drive substantial growth in the pharmaceutical and biotechnology industries, as they work to provide vaccines and treatment drugs for this global health crisis. This growth is also anticipated to have a significant impact on related markets, such as the anthrax vaccine market.

Understanding the Anthrax Threat

Anthrax is a disease with both natural and intentional origins. It can be contracted through contact with infected animals, contaminated soil, or even as a result of a bioterrorism attack. This dual threat has placed anthrax at the forefront of efforts to improve biodefense capabilities and public health preparedness.

𝐏𝐫𝐞-𝐛𝐨𝐨𝐤 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐍𝐨𝐰 : https://www.alliedmarketresearch.com/anthrax-vaccine-market/purchase-options

The Role of Anthrax Vaccines

The key to preventing anthrax lies in vaccination. Anthrax vaccines have been developed to protect both military personnel and civilians who may be at risk. They work by priming the immune system to recognize and combat the anthrax bacterium, offering a potent defense against this potentially lethal threat.

Market Insights and Trends

The Anthrax Vaccine Market is a dynamic space, shaped by various factors:

Growing Awareness: Increased awareness about the potential threats of anthrax has driven governments and organizations to invest in anthrax vaccines as a proactive measure.

Military Applications: Anthrax vaccines play a pivotal role in military preparedness, particularly for troops deployed in regions where anthrax exposure is a risk.

Biotechnology Advances: Continuous advancements in biotechnology and vaccine research are leading to the development of more effective and efficient anthrax vaccines.

Emerging Markets: Anthrax vaccines are also becoming more accessible to developing nations, contributing to global health security.

Protecting Lives and Livelihoods

The role of anthrax vaccines in protecting lives is evident, but the protection of livelihoods should not be underestimated. In regions where anthrax is a known threat, livestock industries are particularly vulnerable. Anthrax vaccines for animals, which help prevent the spread of the disease, are crucial for sustaining agriculture and economic stability.

𝐈𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐞𝐝 𝐭𝐨 𝐏𝐫𝐨𝐜𝐮𝐫𝐞 𝐭𝐡𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭? 𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐁𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠 : https://www.alliedmarketresearch.com/purchase-enquiry/12033

In Conclusion

The Anthrax Vaccine Market is not just about pharmaceuticals and biotechnology; it's about the collective effort to safeguard lives and livelihoods. The insights derived from this market are instrumental in understanding evolving threats and developing strategies to counter them effectively. As biotechnology advances and global collaboration strengthens, we can anticipate more robust and accessible solutions to protect against anthrax.

In an ever-changing world, where health security is a top priority, anthrax vaccines are essential tools in our arsenal to ensure that both lives and livelihoods remain safe from this enduring threat.

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

[w-ht-w]

US Policy Master’s degrees: why and when?

[background + goal] “may impact what degree to get (e.g. subject, location, type of graduate degree).” (1)

Exploration: Policy master’s allow you to quickly explore different policy areas by choosing classes from a wide range of topics. While we recommend only doing a policy master’s if you’re reasonably confident you want to work in policy, within policy you don’t need to have fixed priorities when you start graduate school. (1)

To explore the policy domain and build relevant career capital, many college graduates should (try to) do a few relevant internships, fellowships, or early-career jobs before going to graduate school. For example, you might try to get work experience in Congress (see here and here for tips), think tanks, in the executive branch, or in policy-related private sector roles.[28] You should also consider policy fellowships (see database) that are open to or specifically targeted at recent college graduates, such as the Open Philanthropy Technology Policy Fellowship (junior think tank track), the STPI Science Policy Fellowship, the TechCongress Congressional Innovation Scholars Program, the Scoville Peace Fellowship, or the Endless Frontier Fellowship. (1)

Not every impact-oriented organization cares about formal credentials

Many non-policy organizations (including most EA organizations) care less about traditional credentials like graduate degrees relative to just working in the field itself (especially if you can credibly demonstrate your ability to do excellent work). (1)

Experiential alternatives to MPP: complements not substitutes

Alternative ways to get some of the benefits of a master’s degree include internships, fellowships, and junior positions. However, these options are better seen as complements to a policy master’s rather than substitutes—for example, doing a policy internship in undergrad may help you get into a top policy master’s, which together may help you get a prestigious policy opportunity like the Presidential Management Fellowship. (1)

Education alternatives to MPP: Law school, PhD, STEM graduate degrees

Law school may make sense if you (1) want to work as a government lawyer or shape policy through legal advocacy outside of government (or at least want to keep this option open), (2) can get into a top law school, (3) enjoy learning about law and the legal system, and (4) want a high-earning, high-prestige non-policy back-up option.

A PhD can make sense if you (1) want to keep open the option of an academic career, (2) aim for policy positions that require a PhD (e.g. senior science policy and funding roles), (3) can use the PhD to research relevant policy topics, and (4) require PhD funding to attend graduate school. If you want to get a US PhD, we strongly recommend not first getting a master’s degree due to the time costs.[31]

You can also work in policy with STEM graduate degrees, but this is less common. STEM degrees may provide valuable technical knowledge and boost your credibility for science and technology policy work. Yet, while STEM graduates can do high-impact policy work, their degrees are time-intensive and not designed to prepare them for a policy career (in terms of the career capital they build). Thus, we do not generally recommend pursuing a STEM degree for the purpose of working in policy long-term (though policy can be a good option if you want to get, or already got, a STEM degree for other reasons). (1)

General or more specialized policy degree?

MPA and MIA degrees are typically fairly broad and general, while offering some specializations.[4] There are also more specialized policy degrees on topics like biodefense. We usually recommend more general degrees over highly specialized ones due to their greater option value. While specialized degrees provide more relevant career capital for one specific policy area, they can make switching later more costly. Given that there are many ways to specialize in the course of a more general degree (e.g. through internships, course selection, and research work), we only recommend such specialized degrees if you’re very confident in your policy area/cause of focus. (2)

1. https://forum.effectivealtruism.org/posts/yvsf8DfdQJZ8EadtG/us-policy-master-s-degrees-why-and-when-part-1

Summary

What are policy master’s degrees? They are typically two-year programs in subjects like public policy/administration (MPP/MPA), international relations/security studies, or more technical programs like public health (MPH). Policy master’s fall on a continuum from highly academic to highly practitioner-oriented, with the latter typically being better preparation for a policy career. [read more]

Do I need a master’s to work in policy? Doing a master’s (or other graduate degree) is generally valuable for policy work and often necessary, depending on the institution and role (especially in executive agencies and think tanks). As a policy professional, you’ll most likely want to do a master’s eventually, with limited exceptions such as some career tracks in Congress. [read more]

What’s the value of a master’s for policy work? A master’s builds your career capital for specific paths like policy. The credential is useful and often necessary to get a policy job. Master’s degrees also provide value through learning, skill-building, networking, exploration, and more. The relative importance of these factors depends on your background and goals, and may influence what degree to get (e.g. subject, location, type of graduate degree). [read more]

If I want to do a master’s, when should I do it? We recommend most people to work for 1-3 years before going to graduate school for career exploration and career capital building. A graduate degree can be expensive (in terms of both time and money), so you’ll want to make sure going to graduate school makes sense and that you’re getting the right degree. It’s a common pitfall for people to take the path of least resistance and go to graduate school right after college having little idea what they want to work on longer-term. Graduate school can be a useful “career reset” after which employers care less about whether you worked on unrelated things previously. Also, working before graduate school makes you more competitive for top policy degrees. [read more]

What are the best graduate degrees for policy work? The three most common types of graduate degrees among policy professionals are (1) policy master’s degrees, (2) law degrees, and (3) PhDs. Among the different graduate degree options, a policy master’s degree (e.g. in public policy or international relations) often provides the best balance of benefits over costs for those wishing to advance their policy careers. While policy master’s are the default for policy work, many people reasonably choose law school or a PhD given their specific circumstances. There are also great opportunities for working in policy with a STEM graduate degree, but we don’t generally recommend doing a STEM PhD for the sake of getting into policy. [read more]

Where should I do a master’s? Our policy master’s database includes ~20 degrees that will set you up well for a policy career. We recommend attending a Washington, DC-based university (especially Georgetown University or Johns Hopkins SAIS). Ideally, you'll work or intern in policy alongside your master’s, and DC is where most federal policy jobs are. Many master’s programs at DC universities are designed to allow students to intern and work while completing their degree (lower workloads, evening classes, etc.). This significantly reduces the opportunity cost of studying. The policy schools of DC universities also have career programming to help you get policy jobs as well as professors, alumni, and classmates with deep government connections. Programs outside of DC score less well on these dimensions, though there are exceptions (e.g. Harvard Kennedy School). Part 2 discusses in detail how to choose where to apply.

Why not do a master’s for policy work? First, if you’re highly uncertain about working in policy, you should likely explore more first before doing a policy master’s. While a master’s is often seen as broadly favorable even in non-policy jobs, the case for getting a policy master’s is much stronger if you’re confident you want to work in policy. Second, depending on your circumstances you may want to get a law degree or PhD instead of a policy master’s. [read more]

2. https://forum.effectivealtruism.org/posts/q5vFSbzz5BoymFfPp/us-policy-master-s-degrees-top-programs-applications-and

3. Notes on personal fit (general):

https://80000hours.org/articles/personal-fit/

4. Tips on networking in DC: https://forum.effectivealtruism.org/posts/qPvZJkcqvGAeFt3o6/takeaways-on-us-policy-careers-part-2-career-advice#On_networking_often_and_well

5. fellowship database: (see database)

[bjdefensesingapore]

BJdefense Biodefense System Applies to Education and Child Care Industry

Where our kids go, so do viruses and bacteria. To create the best environment for learning, our DHP technologies developed to improve schools’ indoor air quality hence reducing the health risks in school. There are many ways for getting pure air quality into the educational sectors and the DHP technologies seems very effective from all aspects. While children are going to the school and interacting with their friends and teacher during the study and play time, it's necessary to have good and quality air for the children health. Thus the new range of Biodefense System Applies to education and child care industry effectively work into the indoor and outdoor educational premises.

How Our Biodefense System is Different?

Lets explore about the top advantages and insights of our Biodefense System that not only applies to the education and child care sectors, but also applies to many other industries including Commercial spaces, Church, Office Spaces, Sports and Recreation Sectors, Food Processing Services, Residential Areas, Lifestyle and Entertainment Sectors, Healthcare sectors and many more.  

24/7/365 Protection

Naturally Safe

Commands the Room

Low Maintenance

GUARANTEED RESULTS

EXPERIENCED IN COMBATING VIRUSES

Are you looking for the best disinfection services in Singapore? then visit to our website https://bjdefense.sg/ or call us at: +65 68412986 for more details.